Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

(2016) Henrik Klitgaard et al.   EPILEPSIA

Exploring the Interaction of SV2A with Racetams Using Homology Modelling, Molecular Dynamics and Site-Directed Mutagenesis

(2015) Joanna Lee et al.   PLoS One

The Human Synaptic Vesicle Protein, SV2A, Functions as a Galactose Transporter inSaccharomyces cerevisiae

(2014) Marianna Madeo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays

(2013) V Daniels et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synaptic vesicle protein 2A: basic facts and role in synaptic function

(2013) Julieta Griselda Mendoza-Torreblanca et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Lactose Permease and the Alternating Access Mechanism

(2011) Irina Smirnova et al.   BIOCHEMISTRY

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam

(2011) Anna L. Meehan et al.   JOURNAL OF NEUROPHYSIOLOGY

Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A

(2011) Amy Nowack et al.   PLoS One

SV2 regulates neurotransmitter release via multiple mechanisms

(2010) Amy Nowack et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Further Assessment of 17 -Ethinyl Estradiol as an Inhibitor of Different Human Cytochrome P450 Forms in Vitro

(2009) S.-Y. Chang et al.   DRUG METABOLISM AND DISPOSITION

Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam

(2009) Rafal M. Kaminski et al.   EPILEPSIA

Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission

(2009) Xiao-Feng Yang et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Visualization of SV2A conformations in situ by the use of Protein Tomography

(2008) Berkley A. Lynch et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

New molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels

(2008) Michael A. Rogawski et al.   Current Neurology and Neuroscience Reports

Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy

(2008) Erwin A. van Vliet et al.   EPILEPSIA

Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons

(2008) Min Dong et al.   MOLECULAR BIOLOGY OF THE CELL